Accumulating evidence has shown that RIG-I participates in cellular damage and the occurrence and development of many diseases, such as acute myeloid leukemia (AML), hepatocellular carcinoma, lupus nephritis, immunoglobulin A nephropathy, Crohn’s disease, rheumatoid arthritis, and cardiovascular diseases (CVD) (12–18). Here, RIGI is linked to acute myeloid leukemia.